Clinical trial

An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease

NCT06379646

Study summary

ClinicalTrials.gov

An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: NA

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

OTHER · Unmapped registry intervention YTS109 Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2024-04-24

PhaseNA

Conditions

Systemic Lupus Erythematosusverified · MONDO: systemic lupus erythematosus

Systemic Sclerosisverified · MONDO: systemic sclerosis

Inflammatory Myopathyunresolved

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitisverified · MONDO: anti-neutrophil cytoplasmic antibody-associated vasculitis

Antiphospholipid Syndromeverified · MONDO: antiphospholipid syndrome

Sjogren's Syndromecandidate · MONDO: Sjogren syndrome

Interventions

YTS109OTHER

Sponsors & collaborators

China Immunotech (Beijing) Biotechnology Co., Ltd.lead sponsor

Shanghai Changzheng Hospitalcollaborator

Mapped research locations

ShanghaiShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06379646 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.